Introduction
============

In June 2009, the concept of transient ischemic attack (TIA) was newly defined by the American Heart Association/American Stroke Association, as brief episodes of neurologic dysfunction that are induced by ischemia of a focal brain region, or retina, spinal cord, without causing any acute infarction for the body 1). According to previous studies, minor stroke has been defined according to various criteria. Clinical studies on minor stroke use \<3 of the current National Institutes of Health Stroke Scale (NIHSS) score as a common criterion. In China, there are 3 million new patients with onset stroke each year, of which 30% are minor strokes ([@b2-etm-0-0-4459],[@b3-etm-0-0-4459]). In addition, 2 million individuals are diagnosed with TIA ([@b1-etm-0-0-4459],[@b4-etm-0-0-4459]). TIA/minor stroke patients bear high-risk recurrent and disabling cerebral stroke at an early stage. Studies have demonstrated that stroke has a recurrence rate of 10--20% within 3 months and usually occurs within the first 2 days after the initial onset ([@b5-etm-0-0-4459],[@b6-etm-0-0-4459]). Therefore, early intervention is critical for TIA/minor stroke patients.

Antiplatelets taken at an early stage can reduce the risk of ischemic events. The latest American guidelines suggest taking an initial oral dose of 325 mg of aspirin (ASA) (class I; level of evidence A within 24--48 h. However, the efficacy of clopidogrel (Clop) requires further study (class IIb; level of evidence C) ([@b7-etm-0-0-4459]). In 2010, Hankey and Eikelboom meta-analysis demonstrated that treatment with Clop + ASA was immediately more effective than treatment with ASA alone, and the risk of bleeding is not significantly increased when acute ischemic stroke and TIA patients are at the highest risk of recurrent strokes ([@b8-etm-0-0-4459]).

Based on the Cochrane system, this study aimed to explore the efficacy of Clop + ASA in large scale clinical studies published in recent years for preventing major ischemic vascular events and to characterize the associated risk of potential hemorrhagic events when taken early by TIA/minor stroke patients with a high-risk stroke recurrence and low-risk bleeding.

Materials and methods
=====================

### Experimental procedures

As a systematic review and meta-analysis of published research, no patient consent or ethical approval was required for the study. The design and implementation of this study conformed to the criteria of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) ([@b9-etm-0-0-4459]).

### Eligibility criteria

Research that met the requirements below was included in the study: ⅰ) the study design of the reviewed research is a randomized controlled trial (RCT); ⅱ) patients: TIA/minor stroke patients aged ≥18; ⅲ) interventions: the trial group received Clop + ASA, while the control group received ASA alone; and iv) outcomes: incidence of recurrent stroke, vascular mortalities, myocardial infarction (MI), and major hemorrhagic events.

Exclusion criteria for the study were: ⅰ) unpublished studies; ⅱ) studies without assessment of the measurement indexes; ⅲ) studies with missing data for which statistical analysis cannot be performed; and ⅳ) repeatedly published studies or general reviews.

### Search strategy

Databases listed as below were searched independently by two researchers J.T. and M.Z.Z. (PubMed, Cochrane, EMBase, Medline, and Web of Science) to confirm eligible studies. The following keywords were used: aspirin, antiplatelet therapy, cerebral ischemia, clopidogrel, minor stroke, randomized controlled trial and transient ischemic attack. The screening study was conducted on the screened full-text in order to evaluate additional possible eligible trials.

The studies were independently screened and verified in accordance with the inclusion as well as exclusion criteria. Titles and abstracts were first reviewed to exclude studies that did not comply with the inclusion criteria. For the studies that were potentially eligible, a second screening was conducted by reading the whole text. Any disagreement was solved by a third reviewer (CKH) through consultation.

### Data extraction and measurement of outcome

A piloted extraction datasheet was employed with the following information covered: research title, number of patients, average age of patients, percentage of male patients, received drug dose of the trial group, received drug dose of the control group, time interval from onset of symptoms to entering studies, treatment duration, and percentage of patients lost to follow-up.

### The investigators extracted all data from the reports

Any disagreement was settled through consultation. When necessary, we contacted the corresponding authors by e-mail to gain accurate data. The primary outcome encompassed recurrent stroke, and MI and vascular mortalities were the secondary outcomes, and major hemorrhagic events were for the safety outcome.

### Evaluation of risk of bias and the assessment of the quality of included research

With reference to version 5.1.0 of the Cochrane Handbook for Systematic Reviews of Interventions, risk of bias was assessed for this study ([@b10-etm-0-0-4459]). After reviewing all included articles, a level of unclear, low or high was assigned to the following areas: ⅰ) random sequence generation; ⅱ) blinding of personnel and participants; ⅲ) allocation concealment; ⅳ) blinding of outcome assessment; ⅴ) selective reporting; and ⅵ) incomplete outcome data, and other sources of bias.

The assessment of the quality of the research was conducted using the GRADE form ([@b11-etm-0-0-4459]). Evidence was divided into the following levels: high quality (our confidence in the estimated effect will unlikely be changed by further research), moderate quality (our confidence in the estimated effect is likely to be changed by further research), low quality (our confidence in the estimated effect is very likely to be changed by further research), very low quality of the evidence (we remain quite uncertain about the estimated effect).

### Statistical analysis

The relative risk was estimated with a 95% confidence interval for binary outcomes. I2 was used in tests for homogeneity. I2 above 50% suggested significant heterogeneity and that the random effects model was expected to be employed, and if not the fixed effect model was to be employed ([@b12-etm-0-0-4459]). When significant heterogeneity was present, sensitivity analysis was used to identify potential sources of heterogeneity. If a study was included and the total RR changed substantially, this suggested that the study had a large bias and the result should be interpreted carefully. Based on the sample size, cumulative meta-analysis was used to evaluate the influence of citing studies with large sample size on the incorporated result. The Eggers test and Eggers funnel plot were performed for assessing any publication bias in the studies included ([@b13-etm-0-0-4459]). Results were assumed statistically significant when P\<0.05. RevMan 5.2 and R 3.1.1 were used to perform the statistical analyses.

Results
=======

### Selection of studies and their characteristics

The retrieval and screening results of this study are shown in [Fig. 1](#f1-etm-0-0-4459){ref-type="fig"}. A total of 168 relevant potential studies were obtained through a preliminary screening, while 131 studies were excluded by reading of their titles and abstracts. The full contents of the remaining 37 studies were reviewed, with 32 of them eliminated (27 did not conform to the criteria, 3 were systematic reviews, and 2 were absent of data). Five RCT studies conforming to the criteria were selected for the meta-analysis.

Main characteristics of the 5 RCT studies used for the meta-analysis are shown in [Table I](#tI-etm-0-0-4459){ref-type="table"}. The studies were published from 2005 to 2014; 3 were carried out in Canada, 1 in China, and 1 in the UK. The sample sizes ranged from 107 to 5,170 (the total sample size was 9,527 cases). The average age of patients in these 5 RCT studies was 62--68 years, with a male predominance (53--69%). The duration from onset of symptoms to inclusion into studies (start of treatment) ranged from 24 h to 3 months (three articles in ≤72 h; two articles within 3 months). The treatment durations ranged from 7 days to 3.5 years (three articles in ≤3 months; two articles in ≤3.5 years).

### Risk of bias and evidence level

The risks of bias of the five aforementioned RCT studies are shown in [Fig. 2](#f2-etm-0-0-4459){ref-type="fig"}. Randomized sequence generation was unclear in ASA failure and Clop + ASA for reduction of emboli in symptomatic carotid stenosis because these studies only described randomization instead of the process of random sequence generation. The remaining studies were assumed to have low risk of bias.

GRADE was employed to evaluate the quality of evidence and recommended level ([Table II](#tII-etm-0-0-4459){ref-type="table"}). The results showed that recurrent strokes, MIs, and vascular mortalities were high quality evidence, while major hemorrhagic events were moderate quality.

### Major outcome: recurrent stroke

The incidence of recurrent stroke in the group of Clop + ASA was 8.38%, while the incidence in the ASA group was 10.99%. Compared with ASA, Clop + ASA resulted in a significantly lower incidence of recurrent stroke of the group with TIA/minor stroke (RR=0.76, 95% CI=0.67--0.87, P\<0.0001, [Fig. 3A](#f3-etm-0-0-4459){ref-type="fig"}). No heterogeneity was present between the trial and control groups (I2=19%). Eggers regression line ([Fig. 3B](#f3-etm-0-0-4459){ref-type="fig"}) was made, and a null hypothesis was tested whether the regression line intercepted 0 or not. No bias was suggested with the use of Eggers test (P for bias turned out 0.72).

Cumulative meta-analysis was performed based on sample sizes ([Fig. 4](#f4-etm-0-0-4459){ref-type="fig"}). The treatment effect was initially large, although after adding studies with large sample sizes, the confidence interval narrowed, and the treatment effect became smaller and stable, albeit the treatment effect was still highly significant (P\<0.0001). This analysis indicated that studies with small sample sizes may overestimate the effect of Clop + ASA in lowering recurrent stroke.

### Secondary outcome: myocardial infarction and vascular mortality

The incidence of MI and vascular mortalities was 2.33% in the Clop + ASA group and 2.13% in the ASA group. Compared with ASA, the incidence of MI as well as vascular mortalities was not significantly increased in the group with Clop + ASA (RR=1.08, 95% CI=0.83--1.41, P=0.56, [Fig. 5A](#f5-etm-0-0-4459){ref-type="fig"}). No heterogeneity was present between the trial and control groups (I2=0%). Eggers regression line ([Fig. 5B](#f5-etm-0-0-4459){ref-type="fig"}) was constructed and did not show evidence of any publication bias with the use of Eggers test (P-value for bias was 0.887).

Cumulative meta-analysis was performed based on sample sizes ([Fig. 6](#f6-etm-0-0-4459){ref-type="fig"}). The total RR was initially unstable as it fluctuated between values of \>1.0 and \<1.0. However, after accumulating additional studies, the total RR became stable and the confidence interval became narrow. This analysis suggested that combination therapy does not increase the incidence of vascular mortalities.

### Safety outcome

The incidence of major hemorrhagic events was 0.33% in the Clop + ASA group and 0.21% in the ASA group. Compared with ASA, the incidence of hemorrhagic events was not increased in the group of Clop + ASA (RR=1.55, 95% CI=0.72--3.36, P=0.26, [Fig. 7A](#f7-etm-0-0-4459){ref-type="fig"}). No heterogeneity was present between the trial and control groups (I2=0%). Eggers regression line ([Fig. 7B](#f7-etm-0-0-4459){ref-type="fig"}) was plotted and the Eggers test did not suggest any publication bias (P-value for bias was 0.9723).

Cumulative meta-analysis was performed based on sample sizes ([Fig. 8](#f8-etm-0-0-4459){ref-type="fig"}). The treatment effect was large at the beginning, although after adding studies with large sample sizes, the confidence interval narrowed, and the treatment effect became smaller and stable. This analysis suggested that combination therapy does not increase the incidence of major hemorrhagic events.

Discussion
==========

Of two relevant meta-analyses published in 2012, one showed that dual antiplatelet therapy may lower the incidence of recurrent stroke and vascular events along with total mortalities, without increasing the risk of hemorrhage when compared with mono-antiplatelet therapy for stroke/TIA patients ([@b19-etm-0-0-4459]). However, another meta-analysis showed the opposite result, namely patients with vascular disease taking Clop + ASA may experience an increased risk of fatal hemorrhage ([@b20-etm-0-0-4459]). Therefore, the effects of the two antiplatelet drugs when used in combination require further study. Since a significant amount of research results have been reported in recent years, we evaluated the safety and efficacy of treatment with Clop + ASA compared with ASA alone for TIA/minor stroke patients.

The primary and secondary outcomes of this study show that the incidence of recurrent stroke can be significantly decreased with the treatment of Clop + ASA (RR=0.76, 95% CI=0.67--0.87, P\<0.0001), and MI and vascular mortalities is not significantly changed by such treatment (RR=1.08, 95% CI=0.83--1.41, P=0.56). These findings are inconsistent with the results of previous meta-analyses ([@b19-etm-0-0-4459],[@b20-etm-0-0-4459]). Transcranial Doppler ultrasound recordings provided supportive evidence in these studies as the number of microembolic signals is proportional to recurrent stroke and risk of other vascular events. Both CARESS ([@b16-etm-0-0-4459]) and Clop + ASA for infarction reduction (CLAIR) ([@b21-etm-0-0-4459]) demonstrate that compared with ASA alone, combination therapy of Clop + ASA significantly reduces microembolic signals. Therefore, the risks of recurrent stroke as well as other vascular events are reduced with combination therapy as well.

The safety outcomes show that Clop + ASA does not result in an increase in the risk of major hemorrhagic events (RR=1.55, 95% CI=0.72--3.36, P=0.26). Possible reasons for the inconsistency with the results from other studies include: ⅰ) selection of patients: the population in this study were TIA/minor stroke patients who suffered from a high risk of recurrent ischemic events at an early stage and were at low risk of hemorrhages. However, several other studies included other types of stroke patients or patients with other vascular pathologies. Thus, the potential risks of bleeding in patients from these studies were inherently higher. ⅱ) Drug dosage and duration of treatment: in the SPS3 study, the drug dosage was 325 mg/day and treatment duration was 3.5 years ([@b18-etm-0-0-4459]). These treatment parameters are greater than those from most other studies, thus possibly leading to an increase in major hemorrhagic events in the results.

Combining Clop + ASA is a potent antiplatelet therapy. Therefore, it is necessary to balance their therapeutic effects with potential hemorrhagic risks to optimize the benefits for patients. The results suggest that taking Clop + ASA early appears to be a safe and effective therapy for TIA/minor stroke patients. We believe that the ongoing POINT study ([@b22-etm-0-0-4459]) in the United States and other similar studies may provide evidence to support our hypothesis in the future.

This study has the following limitations: ⅰ) because of the limited amount of research in this field, this meta-analysis only included five studies, therefore, it is difficult to make reliable conclusions; ⅱ) only TIA/minor stroke patients and Clop + ASA vs. ASA therapy are included, and as a result, the narrow scope may have an impact on the conclusion from extrapolation; ⅲ) among patients in the included studies, between the onset of symptoms to inclusion in their respective studies occurred at various time points. Start time for treatment ranged from 24 h to 3 months after initial symptoms. Early treatment can lead to improved prognosis. Thus, the differences in start time of treatment between the studies may affect the final treatment effect; and ⅳ) the dosages of Clop + ASA and treatment times in the included studies were highly variable. Since higher doses of Clop + ASA given for prolonged periods of time increase the risk of bleeding complications, the wide range may contribute to differences in results between our study and others.

In conclusion, future research should focus on determining: ⅰ) whether Clop + ASA therapy is also suitable for other types of ischemic stroke; ⅱ) an appropriate treatment window for TIA/minor stroke patients with Clop + ASA; and ⅲ) the optimal treatment dosage and duration of Clop + ASA for patients with a recent TIA/minor stroke. Future large-scale clinical trials may provide answers to these questions and guide evidence-based approaches for the treatment of this disease.

This study was supported by Research and Development Project of Xiangyang in 2013 (no. 201302) and Scientific Research Project of Hubei Provincial Department of Education in 2014 (B2014051).
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###### 

Design features and baseline characteristics of participants.

  Study name   No.     Mean age (years)   Men (%)   Treatment group and dose                                                               Comparison group and dose             Treatment onset   Treatment duration   Lost to follow-up (%)   Refs.
  ------------ ------- ------------------ --------- -------------------------------------------------------------------------------------- ------------------------------------- ----------------- -------------------- ----------------------- -----------------------
  CHANCE       5,170   62                 66        Asp (76--300 mg load then 75 mg od first 12 days) + Clop (300 mg load then 75 mg od)   Asp (76--300 mg load then 75 mg od)   72 h              90 days              0.7                     ([@b14-etm-0-0-4459])
  PASTER         392   68                 53        Asp (81 mg od) + Clop (300 mg load then 75 mg od)                                      Asp (81 mg od)                        24 h              90 days              1.79                    ([@b15-etm-0-0-4459])
  CARESS         197   65                 69        Asp (75 mg load) + Clop (300 mg load then 75 mg od)                                    Asp (75 mg od)                        72 h              7 days               None                    ([@b16-etm-0-0-4459])
  Failure        888   66                 65        Asp (325 mg od) + Clop (75 mg od)                                                      Asp (325 mg od)                       150 days          3.5 years            NR                      ([@b17-etm-0-0-4459])
  SPS3         3,020   63                 65        Asp (325 mg od) + Clop (75 mg od)                                                      Asp (325 mg od)                       150 days          3.5 years            NR                      ([@b18-etm-0-0-4459])

od, once daily; NR, not reported.

###### 

Clop + ASA compared with ASA for TIA/minor stroke patients.

                              Illustrative comparative risk (95% CI)                                                                           
  --------------------------- ---------------------------------------- ------------------------------------------ -------------- ------------- ----------
  MI and vascular mortality   Study population                                                                                                 
                              21/1,000                                 23/1,000                                   RR=1.08        9,328         ++++
                                                                       (18--30)                                   (0.83--1.41)   (5 studies)   High
                              Moderate                                                                                                         
                              38/1,000                                 41/1,000                                                                
                                                                       (32--54)                                                                
  Stroke recurrence           Study population                                                                                                 
                              110/1,000                                84/1,000                                   RR=0.76        9,328         ++++
                                                                       (74--96)                                   (0.67--0.87)   (5 studies)   High
                              Moderate                                                                                                         
                              117/1,000                                89/1,000                                                                
                                                                       (78--102)                                                               
  Major hemorrhage            Study population                                                                                                 
                              2/1,000                                  3/1,000                                    RR=1.55        9,527         +++−
                                                                       ([@b2-etm-0-0-4459]--[@b7-etm-0-0-4459])   (0.72--3.36)   (5 studies)   Moderate
                              Moderate                                                                                                         
                              2/1,000                                  3/1,000                                                                 
                                                                       ([@b1-etm-0-0-4459]--[@b7-etm-0-0-4459])                                

Clop, clopidogrel; ASA, aspirin; TIA, transient ischemic attack; MI, myocardial infarction.
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